On April 19,Hisuni pharmaceutical issued an announcement stating that the company had recently received tofacitib citrate tables obtain a drug registration certificate. Tofacitinib citrate tables are suitable for moderate to severely active rheumatoid arthritis (RA) adult patients with insufficient or intolerable methotrexate and can be improved with methotrexate or other non_biological improvements disease antirheumatic drugs (DMARD) are used in combination. Hisun pharmaceutical's tofacitib citrate tablets were approved by the state food and drug administration according to how this may sound reader to the new category4, and they were deemed to have passed the consistency evaluation. Tofacitinib citrate was developed by pfizer and was approved by the US FDA on November 6, 2012.under the trade name XELJANZ domestic manufacturers of tofacitib citrate tablets include qilu pharmaceutical co., Ltd and hunankelun pharmaceutical co;ltd, etc. After inquiring about the IMS database, the global sales of tofacitib citrate tablets in 2019 were approximated US$3,79,204,500 of which domestic sales were approximately US$9,800,000 the global sales in 2020 were approximately US$3,584,400 of which domestic sales were approximately it is 18,244,400 US dollars.
On January 15, 2019, the state food and drug administration accepted the company's application for drug registration of tofacitib citrate tablets. Up to now, hisun pharmaceutical has invested about 19,47 million yuan in the drug research and development project.
Comments
Post a Comment